Clinical trials: Cancer Breast
Breast Cancer, Hormone Receptor Positive Tumor
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
The purpose of this study is to evaluate the biological effects of abemaciclib in combination with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone in the tumors of postmenopausal women with…
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Early-Stage Breast Carcinoma
- Trial name
- neoMONARCH (NCT02441946)
- Testing
- Abemaciclib, Loperamide, Anastrozole
- Where
- 66 sites in United States, Austria and 8 more
- Volunteers
- 224 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
First Line Therapy for Patients With Metastatic Breast Cancer
The purpose of this study is to determine the toxicity and anti-tumor activity of nab-paclitaxel 100mg/m^2 administered weekly in a 4-week cycle as first line therapy to patients with metastatic breast cancer who received taxanes…
- Trial name
- NCT00456846
- Testing
- ABI-007
- Where
- 14 sites in Canada
- Volunteers
- 123 people
- Sponsor
- Celgene
Breast Cancer
Evaluation of BIS for Quantification of Lymphedema
The purpose of this study is to determine whether measuring the fluid in your arms using Bioimpedance Spectroscopy is as effective at detecting and monitoring lymphedema as measurements with the Perometer.
- Trial name
- NCT01544335
- Testing
- Bioimpedance Spectroscopy
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Massachusetts General Hospital
Breast Neoplasm Female, Postoperative Pain Management
PECS II vs. MTP for Analgesia After MRM
This randomized controlled study aims to compare the analgesic efficacy of the ultrasound-guided modified pectoral nerve block (PECS II) and the midpoint transverse process to pleura (MTP) block in female patients undergoing…
- Trial name
- NCT06187909
- Testing
- PECS II BLOCK, MTP BLOCK
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Ain Shams University
HER2-Positive Early Breast Cancer
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
This is a Phase II, randomized, multicentre, multinational, open-label, cross-over study in adult patients who have completed neoadjuvant chemotherapy with neoadjuvant pertuzumab and trastuzumab and have undergone surgical…
- Trial name
- PHranceSCa (NCT03674112)
- Testing
- Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 40 sites in United States, Argentina and 15 more
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Thyroid Cancer
3-D Super Resolution Ultrasound Microvascular Imaging
This is a 3-arm single center study of 45 patients. These cohorts will include 15 breast patients scheduled to undergo a biopsy, and 15 thyroid patients scheduled to undergo fine needle aspiration, biopsy, or thyroidectomy that…
- Trial name
- NCT04136912
- Testing
- Definity, Acoustic Angiography
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
- Trial name
- HEART (NCT00537771)
- Testing
- Anastrozole, Tamoxifen
- Where
- 16 sites in China
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Breast Cancer
Dietary Fat, Eicosanoids and Breast Cancer Risk
The primary objective of this investigation is to determine whether diets designed to increase plasma n3 concentrations (a low fat diet, with or without n3 fatty acid enrichment), will favorably affect sex hormone distribution in…
- Trial name
- NCT01824498
- Testing
- Low Fat diet, Low Fat high n3 diet, High Fat Diet
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- USDA Grand Forks Human Nutrition Research Center
Sexual Dysfunction, Sexual Arousal Disorder
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
- Conditions
- Sexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological, Breast Cancer
- Trial name
- NCT03592121
- Testing
- AB-101
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Applied Biology, Inc.
Screening Mammogram
Increasing Breast Cancer Screening in Chinese Immigrants
The long-term goal of this research is to increase breast cancer screening rates in NYC Chinese immigrants. The researchers plan to accomplish this objective by developing and testing a culturally- and linguistically-adapted…
- Trial name
- NCT05089292
- Testing
- Narrative breast health education
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
This trial studies the effectiveness of two interventions on patient reported outcomes of patient centered communication and decision making about breast cancer treatment.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- SHARES (NCT04549571)
- Testing
- Decision Aid iCanDecide - ESE website, Decision Aid iCanDecide - S website, Therapeutic Conventional Surgery
- Where
- 27 sites in United States
- Volunteers
- 614 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors
This study will implement therapeutic bright light that is tailored to the individual's circadian typology and will estimate its effects on circadian rhythms, 4 common cancer-associated symptoms, and impact on quality of life in…
- Trial name
- NCT03304587
- Testing
- Polysomnography (PSG), Rectal thermistor 400 Series, Bright blue-green light
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
This phase II trial is studying how well giving tipifarnib together with fulvestrant works as second-line therapy in treating postmenopausal women with hormone receptor-positive inoperable locally advanced or metastatic breast…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00082810
- Testing
- fulvestrant, tipifarnib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
The goal of this study is to evaluate safety and healing time after nipple-areolar complex (NAC) reconstruction with the BioAesthetics' decellularized human nipple-areolar complex (dcl-hNAC) graft in patients who have had…
- Trial name
- NCT04534010
- Testing
- NACgraft
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Stanford University
Breast Cancer
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is safe and effective in the treatment of locally advanced/metastatic breast cancer following treatment with a CDK 4/6…
- Trial name
- TRINITI-1 (NCT02732119)
- Testing
- Ribociclib, Everolimus, Exemestane
- Where
- 25 sites in United States
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Quantitative Subharmonic Breast Imaging
This is a non-randomized trial of 450 women with a breast abnormality, who are scheduled for a breast biopsy of this abnormality. The study will be conducted at two clinical sites.
- Trial name
- NCT01490892
- Testing
- 3D HI and SHI of UCA
- Where
- 2 sites in United States
- Volunteers
- 219 people
- Sponsor
- Thomas Jefferson University
Breast Cancer
Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
The treatment of the patients with recurrent and metastatic breast cancer remains a major problem. There is still a lack of effective targeted therapy for Her-2 negative breast cancer.Based on the present researches on the…
- Trial name
- NCT02878057
- Testing
- Apatinib
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Leukemia, CLL
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
The goal of this clinical research study is to learn if treatments to kill cancer cells including lenalidomide and/or radiation therapy can help to control symptoms such as sleep problems and fatigue in patients with chronic…
- Trial name
- NCT00792077
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00665457
- Testing
- filgrastim, capecitabine, celecoxib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Nebraska